Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

47 results about "Phenylcarbamates" patented technology

Phenyl esters of carbamic acid or of N-substituted carbamic acids. Structures are similar to PHENYLUREA COMPOUNDS with a carbamate in place of the urea.

Method for determining impurity F in captopril tablets through high performance liquid chromatography

The invention discloses a method for determining an impurity F in captopril tablets through high performance liquid chromatography and belongs to the technical field of pharmaceutical analysis. Detection is performed under the conditions as follows: an amylase-tris(5-chloro-2-methyl phenyl carbamate) coated chromatographic column is used, normal hexane-absolute ethyl alcohol-trifluoroacetic acid serves as a mobile phase, a volume ratio of the normal hexane to absolute ethyl alcohol to trifluoroacetic acid is 80:20:0.1, a detection wavelength is 215nm, flow velocity is 1ml/min, a column temperature is 35 DEG C and a sample amount is 20[mu]l. A structural formula of the impurity F is as shown in the description. According to the method disclosed by the invention, the content of the impurityF in the captopril tablets can be quantitatively determined, so that the quality of the captopril tablets is effectively controlled. According to the method provided by the invention, the captopril and the impurity F can be proved to be effectively separated in a system suitability solution, and the method has high precision and high separation degree. A signal to noise ratio of a self-contrast solution is more than 10, and if the sample contains the impurity F, the impurity F can be detected.
Owner:ZHENGZHOU TAIFENG PHARMA CO LTD

Novel process for the preparation of phenylcarbamates

This invention relates to a process for the preparation of an aminoalkyl phenyl carbamate compound of formula 1,wherein R1 and R2 independently are hydrogen or C1-6 alkyl; R3 and R4 are the same or different and each is a lower alkyl; or R3 and R4 together with the nitrogen to which they are attached form a cyclic moiety of a three to eight-member ring, with or without a hetero atom like nitrogen or oxygen; R5 and R6 independently are hydrogen, linear, branched or cyclic C1-6 alkyl, allyl, propargyl or benzyl; or R5 and R6 together with the nitrogen to which they are attached form a cyclic moiety of three to eight member ring, with or without a hetero atom like nitrogen or oxygen; the carbon center marked with “*” is racemic or enantiomerically enriched (R)- or (S)-configuration; and pharmaceutically acceptable addition salts, and crystalline and amorphous forms thereof comprising the steps of:i) converting an amine R5R6NH to a carbamoylimidazolium salt of formula 3wherein R5 and R6 are as defined above; X− is a counterion and R7 is an alkyl or aryl group;ii) reacting in a solvent at a controlled reaction temperature the compound of formula 3 with a compound of formula 4,wherein R1, R2, R3, R4 and “*” are as defined above to give the compound of formula 1; andiii) isolating the compound of formula 1.
Owner:APOTEX PHARMACHEN INC

Process for the preparation of phenylcarbamates

This invention relates to a process for the preparation of an aminoalkyl phenyl carbamate compound of formula 1,wherein R1 and R2 independently are hydrogen or C1-6 alkyl; R3 and R4 are the same or different and each is a lower alkyl; or R3 and R4 together with the nitrogen to which they are attached form a cyclic moiety of a three to eight-member ring, with or without a hetero atom like nitrogen or oxygen; R5 and R6 independently are hydrogen, linear, branched or cyclic C1-6 alkyl, allyl, propargyl or benzyl; or R5 and R6 together with the nitrogen to which they are attached form a cyclic moiety of three to eight member ring, with or without a hetero atom like nitrogen or oxygen; the carbon center marked with “*” is racemic or enantiomerically enriched (R)- or (S)-configuration; and pharmaceutically acceptable addition salts, and crystalline and amorphous forms thereof comprising the steps of:i) converting an amine R5R6NH to a carbamoylimidazolium salt of formula 3wherein R5 and R6 are as defined above; X− is a counterion and R7 is an alkyl or aryl group;ii) reacting in a solvent at a controlled reaction temperature the compound of formula 3 with a compound of formula 4,wherein R1, R2, R3, R4 and “*” are as defined above to give the compound of formula 1; andiii) isolating the compound of formula 1.
Owner:APOTEX PHARMACHEN INC

Diclazuril enantiomer chiral chromatographic separation analysis method

ActiveCN109001326AChiral Chromatographic Separation RealizationEasy to separateComponent separationCelluloseChromatographic separation
The invention discloses a diclazuril enantiomer chiral chromatographic separation analysis method. The separation analysis method comprises the following steps of carrying out pretreatment on a chiralstationary phase, taking normal hexane, trifluoroacetic acid and lower alcohol as a mobile phase, and carrying out liquid phase chromatography separation analysis, wherein the pretreatment refers towashing of the chiral stationary phase by using the mobile phase, the washing time is not less than 2 hours, and the washing flow rate is not greater than 0.5mL.min-1; the chiral stationary phase is bonding type to parachloro-phenylcarbamoyl beta-cyclodextrin, coating type cellulose tri(3, 5-dimethyl phenylcarbamate) or coating type straight-chain starch tri(3, 5-dimethyl phenylcarbamate); the lower alcohol is ethanol, n-propyl alcohol, isopropanol or n-butyl alcohol; and the volume ratio of normal hexane to the lower alcohol is 50-80: 50-20. According to the chiral chromatographic separationanalysis method provided by the invention, the chiral stationary phase is pretreated, and the normal hexane, the trifluoroacetic acid and the lower alcohol are used as the mobile phase, so that the chiral chromatographic separation of the diclazuril enantiomer is realized.
Owner:广州研创生物技术发展有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products